Key result
PGE2 infusion rapidly raises arterial oxygen saturation in neonates with cyanotic CHD.
Why the study?
Prostaglandin E2 has been used to maintain ductus arteriosus patency in neonates with cyanotic congenital heart disease due to obstructive right heart malformations to improve oxygenation before surgery.
Does Prostaglandin E2 infusion improve arterial oxygen saturation in neonates with cyanotic congenital heart disease?
Design
Case series
Follow-up
Post-surgery
Authors
Loading...
May support PGE2 for pre-surgical ductal patency in neonates; leaves open need for controlled trials to confirm safety and efficacy.
Case Report (n=4)
Does Prostaglandin E2 infusion improve arterial oxygen saturation in neonates with cyanotic congenital heart disease?
PGE2 infusion effectively maintains ductus arteriosus patency and improves oxygenation as an emergency preoperative therapy in neonates with ductus-dependent cyanotic congenital heart disease.
Olley et al. (1976) conducted a case report in Cyanotic congenital heart disease due to obstructive right heart malformations (n=4). Prostaglandin E2 (PGE2) was evaluated on Arterial oxygen saturation. Prostaglandin E2 infusion produced an immediate and persistent rise in arterial oxygen saturation in four neonates with cyanotic congenital heart disease, allowing successful surgical recovery.
Synapse has enriched one closely related paper. Consider it for comparative context: